David Blakey is currently the CSO of MiNA therapeutics and also is a visiting Professor at the Hammersmith Labs of Imperial College, London. He has almost 30 years experience in the Pharmaceutical industry discovering and developing therapeutic antibodies, small molecule and more recently oligonucleotides. After he obtained a degree in Biochemistry from Oxford University and a PhD in Drug Metabolism from London University he worked as a Post Doc on the optimisation and pharmacology of ricin immunotoxins at the ICRF in London.
In 1987 he joined AstraZeneca (AZ) where he championed the establishment and scientific management of AZ’s first major antibody collaboration with Abgenix/Amgen that led to a number of clinical development candidates. Over his last few years at AstraZeneca as Chief Scientist in Oncology he led a global cross therapy area team on oligonucleotide based therapies. He championed the oligonucleotide area to senior management within AZ leading to collaborations with Ionis, Regulus and Moderna. David joined MiNA therapeutics as CSO in October 2015 to lead the scientific development of their leading small activating RNA (saRNA) platform.
Since joining MiNA their first saRNA, MTL-CEBPA has entered Phase 1 clinical trials in liver cancer. He has over 50 peer reviewed publications where he is the lead or co-author and is currently a Director of the Oligonucleotide Therapeutics Society(OTS).
Company Website: http://minatx.com